Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | CCR8 | P51685 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 5/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | TOP1 | P11387 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359475 | 0.82 | STAT3 (0.49) | CCR1CCR5CCR8TERTMETAP2 | |
| SCHEMBL6394266 | 0.80 | TERT (0.46) | TERTTOP1 | |
| SCHEMBL6393380 | 0.78 | TERT (0.44) | TERTTOP1 | |
| SCHEMBL29822398 | 0.76 | KDM4E (0.46) | CCR1CCR5CCR8TERTMETAP2 | |
| SCHEMBL432185 | 0.76 | KDM4E (0.46) | CCR1CCR5CCR8TERTMETAP2 | |
| SCHEMBL6393600 | 0.76 | TERT (0.42) | TERTTOP1 | |
| SCHEMBL599851 | 0.75 | KDM4E (0.45) | CCR1CCR5CCR8TERTMETAP2 | |
| SCHEMBL9418754 | 0.75 | KDM4E (0.45) | CCR1CCR5CCR8TERTMETAP2 | |
| SCHEMBL29560659 | 0.75 | KDM4E (0.45) | CCR1CCR5CCR8TERTMETAP2 | |
| Magnesium SCHEMBL9418766 | 0.75 | KDM4E (0.45) | CCR1CCR5CCR8TERTMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862936-B1 | OXIDOREDUCTASE REACTION CONTROL USING AMINO SUBSTITUTED BIPYRIDINIUM COMPOUNDS | AMANO ENZYME INC (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-9777299-B2 | Oxidoreductase reaction control and use thereof | AMANO ENZYME INC. (JP) | 2017-10-03 | — | — | US | disclosed |
| EP-2862936-A1 | OXIDOREDUCTASE REACTION CONTROL AND USE THEREOF | Amano Enzyme Inc. (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-20130189347-A1 | DISEASE TREATMENT DRUG | YUASA MAKOTO (JP) | 2013-07-25 | — | — | US | disclosed |
| EP-2601954-A1 | THERAPEUTIC AGENT FOR DISEASE | Yuasa, Makoto (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-20120039987-A1 | NIOSOME HAVING METAL PORPHYRIN COMPLEX EMBEDDED THEREIN, PROCESS FOR PRODUCING THE SAME AND DRUG WITH THE USE THEREOF | MAKOTO YUASA (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20080269184-A1 | Niosome Having Metal Porphyrin Complex Embedded Therein, Process For Producing The Same And Drug With The Use Thereof | YUASA, MAKOTO (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1357946-B1 | PHOTODYNAMIC THERAPY WITH REDUCED FLUENCE RATE | QUADRA LOGIC TECH INC (CA) | 2008-03-26 | — | — | EP | disclosed |
| EP-1731150-A1 | NIOSOME HAVING METAL PORPHYRIN COMPLEX EMBEDDED THEREIN, PROCESS FOR PRODUCING THE SAME AND DRUG WITH THE USE THEREOF | Yuasa, Makoto (JP) | 2006-12-13 | — | — | EP | disclosed |
| US-20050008687-A1 | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same | MAKOTO YUASA (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040266748-A1 | Photosensitizing carbamate derivatives | MIRAVANT PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040072769-A1 | Methods for design and selection of short double-stranded oligonucleotides, and compounds of gene drugs | YIN JAMES QINWEI (US) | 2004-04-15 | — | — | US | disclosed |
| US-6372727-B1 | ADMINISTERING IRON PORPHYRIN TO TREAT AMYOTROPHIC LATERAL SCLEROSIS; TREATING OXIDATIVE INJURY RELATED TO PEROXYNITRITE | UAB RESEARCH FOUNDATION | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189347-A1 | DISEASE TREATMENT DRUG | PPOX, TFRC, SLC40A1 | CCR1 3978/4885CCR5 4591/4885CCR8 4305/4885 |
| US-20120039987-A1 | NIOSOME HAVING METAL PORPHYRIN COMPLEX EMBEDDED THEREIN, PROCESS FOR PRODUCING THE SAME AND DRUG WITH THE USE THEREOF | SOD1, SOD3, GPX1 | CCR1 4311/4885CCR5 4176/4885CCR8 3644/4885 |
| US-20040266748-A1 | Photosensitizing carbamate derivatives | CRY1, CASP3, CRY2 | CCR1 4638/4885CCR5 4741/4885CCR8 4495/4885 |
| US-20080269184-A1 | Niosome Having Metal Porphyrin Complex Embedded Therein, Process For Producing The Same And Drug With The Use Thereof | SOD1, SOD3, GPX1 | CCR1 4328/4885CCR5 4223/4885CCR8 3675/4885 |
| US-20050008687-A1 | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same | GPX4, FECH, PPOX | CCR1 4849/4885CCR5 4454/4885CCR8 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.